(Q35841615)

10 August 2017

1 reference

title

Biological therapies in the systemic management of psoriasis: International Consensus Conference (English)

1 reference

10 August 2017

Sterry W

1

1 reference

10 August 2017

Barker J

2

1 reference

10 August 2017

Boehncke WH

3

1 reference

10 August 2017

Bos JD

4

1 reference

10 August 2017

Chimenti S

5

1 reference

10 August 2017

Christophers E

6

1 reference

10 August 2017

De La Brassinne M

7

1 reference

10 August 2017

Ferrandiz C

8

1 reference

10 August 2017

Griffiths C

9

1 reference

10 August 2017

Katsambas A

10

1 reference

10 August 2017

Kragballe K

11

1 reference

10 August 2017

Lynde C

12

1 reference

10 August 2017

Menter A

13

1 reference

10 August 2017

Ortonne JP

14

1 reference

10 August 2017

Papp K

15

1 reference

10 August 2017

Prinz J

16

1 reference

10 August 2017

Rzany B

17

1 reference

10 August 2017

Ronnevig J

18

1 reference

10 August 2017

Saurat JH

19

1 reference

10 August 2017

Stahle M

20

1 reference

10 August 2017

Stengel FM

21

1 reference

10 August 2017

Van De Kerkhof P

22

1 reference

10 August 2017

Voorhees J

23

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 August 2004

1 reference

British Journal of Dermatology

10 August 2017

1 reference

10 August 2017

151 Suppl 69

1 reference

10 August 2017

3-17

1 reference

Therapeutic strategies for psoriasis.

10 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06070.X

Immunomodulatory drugs for psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06070.X

Advances in systemic therapy for psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06070.X

The pathogenesis of psoriasis: immunological facts and speculations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06070.X

The immunological basis of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06070.X

The immunologic basis for the treatment of psoriasis with new biologic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06070.X

The immunologic and genetic basis of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06070.X

Recombinantly engineered human proteins: transforming the treatment of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06070.X

Biologic therapy for psoriasis: the new therapeutic frontier

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06070.X

Novel immune-based therapies for psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06070.X

A systematic review of five systemic treatments for severe psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06070.X

Current consensus and update on psoriasis therapy: a perspective from the U.S.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06070.X

Therapeutic strategies: rotational therapy and combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06070.X

Current systemic therapies for psoriasis: where are we now?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06070.X

Preclinical evaluation of drug-drug interaction potential: present status of the application of primary human hepatocytes in the evaluation of cytochrome P450 induction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06070.X

Treatment of psoriasis. Part 1. Topical therapy and phototherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06070.X

Quality of life issues in psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06070.X

Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06070.X

An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06070.X

CD4+ T-cell–directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06070.X

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06070.X

Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06070.X

Case reports of heart failure after therapy with a tumor necrosis factor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06070.X

Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06070.X

Cytotoxic and immunologic effects of methotrexate in psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06070.X

Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06070.X

Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06070.X

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06070.X

Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06070.X

Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06070.X

Long term safety of infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06070.X

A randomized trial of etanercept as monotherapy for psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06070.X

Successful treatment of recalcitrant psoriasis with a combination of infliximab and hydroxyurea

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06070.X

Phototherapy treatment of psoriasis today

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06070.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06070.X

Consensus Workshop on the Toxic Effects of Long-term PUVA Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06070.X

The risk of melanoma in association with long-term exposure to PUVA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06070.X

Cyclosporine immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06070.X

Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06070.X

Clinical response to alefacept: results of a phase 3 study of intramuscular administration of alefacept in patients with chronic plaque psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06070.X

Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06070.X

Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06070.X

Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06070.X

Long-term safety of cyclosporine in the treatment of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2004.06070.X

10.1111/J.1365-2133.2004.06070.X

21 January 2018

Identifiers

DOI

1 reference

10 August 2017

1 reference